RxDoctor Payments Data

Christopher Wicker, MD

Internal Medicine · Lexington, SCNPI 1801912829

Payments from drug & device makers

$4,404in general payments, 2019–2025

Across 261 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$615
  • Novo Nordisk$572
  • Lilly USA, LLC$376
  • Amgen$296
  • Pfizer$219
  • Neurocrine Biosciences, Inc.$203
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,404 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$218,530
Medicare patients
4,007
Services billed
11,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban183$131,376
MounjaroTirzepatide112$126,522
JardianceEmpagliflozin147$109,632
TrulicityDulaglutide98$100,328
FarxigaDapagliflozin Propanediol143$99,920
IngrezzaValbenazine Tosylate14$96,581
OzempicSemaglutide31$42,878
XareltoRivaroxaban64$36,033
JanuviaSitagliptin Phosphate44$29,108
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$28,491
Tresiba Flextouch U-200Insulin Degludec35$28,245
LinzessLinaclotide45$23,391
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$22,761
Repatha SureclickEvolocumab23$22,500
Soliqua 100-33Insulin Glargine/Lixisenatide18$20,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$376$226,850210 claims
PfizerEliquis, Celebrex$219$141,748194 claims
AstraZenecaFarxiga, Breztri Aerosphere$615$119,618174 claims
Boehringer IngelheimJardiance$61$109,632147 claims
Neurocrine Biosciences, Inc.Ingrezza$203$96,58114 claims
Novo NordiskOzempic, Rybelsus$572$54,31143 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$77$45,18771 claims
Johnson & JohnsonXarelto$85$36,03364 claims
AbbVieLinzess, Creon$201$35,48256 claims
MerckJanuvia$42$29,10844 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$155$27,21187 claims
Avanir Pharmaceuticals, Inc.Nuedexta$11$20,33413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →